Research programme: tyrosine kinase inhibitors - SuperGen

Drug Profile

Research programme: tyrosine kinase inhibitors - SuperGen

Alternative Names: MP-371

Latest Information Update: 27 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SuperGen
  • Class Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; CSK protein inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Rad51 recombinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 11 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the adverse events and pharmacokinetics a sections
  • 25 Apr 2007 SuperGen receives approval from the FDA to initiate phase I trials of MP 470 in solid tumours
  • 05 Apr 2006 Montigen has been acquired and merged into SuperGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top